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Abstract
Objective: To report the 5-year risk and to identify risk factors for the development of a seminal acute or progressive clinical
event in a multi-national cohort of asymptomatic subjects meeting 2009 RIS Criteria.
Methods: Retrospectively identified RIS subjects from 22 databases within 5 countries were evaluated. Time to the first
clinical event related to demyelination (acute or 12-month progression of neurological deficits) was compared across
different groups by univariate and multivariate analyses utilizing a Cox regression model.
Results: Data were available in 451 RIS subjects (F: 354 (78.5%)). The mean age at from the time of the first brain MRI
revealing anomalies suggestive of MS was 37.2 years (y) (median: 37.1 y, range: 11–74 y) with mean clinical follow-up time
of 4.4 y (median: 2.8 y, range: 0.01–21.1 y). Clinical events were identified in 34% (standard error = 3%) of individuals within
a 5-year period from the first brain MRI study. Of those who developed symptoms, 9.6% fulfilled criteria for primary
progressive MS. In the multivariate model, age [hazard ratio (HR): 0.98 (95% CI: 0.96–0.99); p= 0.03], sex (male) [HR: 1.93
(1.24–2.99); p= 0.004], and lesions within the cervical or thoracic spinal cord [HR: 3.08 (2.06–4.62); p=,0.001] were
identified as significant predictors for the development of a first clinical event.
Interpretation: These data provide supportive evidence that ameaningful number of RIS subjects evolve to a first clinical symptom.
An age,37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.
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Introduction
The radiologically isolated syndrome (RIS) was first introduced
in 2009 [1] to define a relevant cohort of individuals routinely
encountered in clinical practice who are at risk for future
demyelinating events. Formal criteria were generated to enhance
the specificity for accurate classification such that risk factors for
clinical and radiological progression could be appropriately
identified. Even prior to the introduction of RIS criteria [1],
longitudinal clinical data from healthy individuals with incidentally
identified anomalies suggestive of multiple sclerosis (MS) were
described [2], followed by a proposed variant with similar
phenomenology [3]. Subsequent to these early reports, advances
have been made in the characterization of RIS subjects [4–9] and
in our understanding of risk factors for initial symptom develop-
ment [10–12].
However, a current challenge in the global application of
established criteria for RIS involves the accurate classification of
subjects with incidentally identified anomalies highly characteristic
for MS, in comparison to those categorized in medical parlance as
possessing ‘‘unidentified bright objects’’ or non-specific T2-
hyperintensities commonly identified in migraine headache
patients [13] that fulfill MS spatial dissemination requirements
[14]. Efforts to increase the available data that improve upon the
characterization of RIS and risk for symptom manifestation are
not only essential to prevent over diagnosis, but to enhance
medical counseling, surveillance recommendations, and future
research strategies.
This investigation represents an analysis of retrospectively
acquired, non-standardized, multi-national data ascertained from
the Radiologically Isolated Syndrome Consortium (RISC) in an
effort to estimate the risk for an initial clinical event and
understand important risk factors for symptom manifestation.
Methods
Ethics Statement
This investigation was approved by following regulatory
authorities and ethics committees: Committee on Human
Research (University of California, San Francisco, California,
U.S.A.), Mayo Clinic Institutional Review Board (Mayo Clinic,
Rochester, Minnesota, U.S.A.), Institutional Review Boards of Mt.
Sinai School of Medicine (Mt. Sinai School of Medicine, New
York, New York, U.S.A.) and the Barrow Neurological Institute
(Barrow Neurological Institute, Phoenix, Arizona, U.S.A.), Insti-
tutional Review Board of Vall d9Hebron Research Institute (MS
Center of Catalunya Cemcat, Barcelona, Spain), Institutional
Review Board for Human Subjects (University of Florence,
Florence, Italy), Institutional Review Board of the University of
Siena (University of Siena, Siena, Italy), Istanbul University
Cerrahpasa School of Medicine Ethical Committee for Clinical
Research and Studies (University of Istanbul, Istanbul, Turkey),
and the Comite´ de Protection des Personnes (Hoˆpital Pasteur,
Nice, France). Written informed consent was acquired from all
study subjects.
Subjects
Retrospectively identified subjects fulfilling 2009 criteria for RIS
[1], originating from 22 clinical sites within 5 countries, with initial
brain MRI studies revealing incidental anomalies suggestive of
demyelinating disease dated .1990 were included. Data originat-
ed from existing RIS cases within centers and newly identified RIS
cases arising from requested consultations and referrals from
community and academic centers. Table 1 summarizes the
inclusion and exclusion criteria.
In all subjects, demographic characteristics, family history of
MS, detailed historical and current clinical data, key episodes in
their RIS course, comprehensive neurological examination results,
structural neuro-imaging of the brain, and non-standardized blood
test results (i.e. sedimentation rate, anti-nuclear antibody, vitamin
B12 level, homocysteine and methylmalonic acid, rheumatoid
factor, anti-cardiolipin antibody screen, thyroid function studies,
serum angiotensin-converting enzyme, and Lyme disease titers) for
the evaluation of other medical conditions that could explain the
observed lesions on brain MRI were available. Imaging of the
spinal cord and other para-clinical studies (i.e. cerebrospinal fluid
(CSF) analysis, optical coherence tomography, etc.) were variable
amongst individuals and within participating centers.
Neuro-Imaging Studies
In all cases, the original imaging studies on hard films or within.
DICOM files were reviewed to confirm the presence of brain
anomalies. All study subjects possessed one or more MRI studies of
the brain that fulfilled dissemination in space (DIS) criteria for RIS
[1]. Images originated from non-uniform protocols from differing
MRI units and magnetic field strengths (1.5 or 3.0 Tesla (T)) and
were performed at multiple academic, academic affiliated, and
community institutions. All examinations included T1 and T2-
weighted spin-echo sequences in multiple planes of view (axial,
coronal, and sagittal) with or without the administration of
gadolinium. Spinal cord imaging protocols were also heteroge-
neous with T1 and T2-weighted spin-echo sequences in axial and
sagittal planes of view available (with or without gadolinium) and
short tau inversion recovery (STIR) sequences accessible for more
recent imaging studies.
For all MRI studies reviewed, abnormalities within the brain or
spinal cord were initially identified by a neuroradiologist on the
formal interpretation and subsequently examined and verified by
an MS specialist at each clinical site to ensure DIS MRI criteria
were met [1]. A qualitative (i.e. geographical location within the
brain or spinal cord, and morphology of lesions) and quantitative
(i.e. number of T2-foci, presence or absence of gadolinium
enhancement) analysis of the available brain and spinal cord
imaging studies was performed.
Brain MRI studies were assessed for the presence of lesions in
the supratentorial and infratentorial regions, with specific attention
to brainstem structures and the presence of gadolinium enhance-
ment. Lesions within the cervical and thoracic spinal cord were
deemed significant utilizing previously reported criteria [12].
RIS and Risk for a Demyelinating Event
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Procedures
The primary outcome for this investigation was to assess the
impact of demographic, clinical, and radiological metrics on the
time to the first clinical event, defined as the development of an
acute neurological episode localized to the optic nerve, brainstem,
cerebellum, spinal cord, or long sensory or motor tracts, lasting .
24 hours followed by a period of symptom improvement or the
onset of a clinical symptom (e.g. leg weakness) with the temporal
profile revealing at least a 12-month progression of neurological
deficits, across different groups. Multiple sclerosis specialists and
site principal investigators were responsible for confirming
relapses. Quality assurance measures were performed on all
subjects with symptom manifestation to confirm documented
neurological events by evaluating the clinical description, locali-
zation within the CNS, and, when available, the Expanded
Disability Status Scale (EDSS) score.
Subgroups were defined based on demographic factors (i.e. age
at the time of RIS, sex, ethnicity, etc.), baseline brain and spinal
cord MRI characteristics, CSF profiles, and exposure to approved
disease-modifying treatments (DMTs) for MS.
Statistical Analysis
All calculations and statistical analyses were performed using
SPSS for Windows, version 16.0 (SPSS, IBM, Armonk, New York,
U.S.A.).
Means with standard deviations (SD) were acquired to summarize
the demographic, clinical and radiological data, when appropriate.
The time from RIS diagnosis to the first acute or initial
symptom resulting in a progressive clinical course was estimated
utilizing Kaplan-Meier survival analyses. Log-rank tests were used
to compare survival data between groups at univariate analysis.
Multivariate Cox regression models were created to assess the
independent predictive value of demographic characteristics (i.e.
sex, ethnicity, age at the time of RIS diagnosis), clinical data (i.e.
MS family history, exposure to approved DMTs for MS, CSF
profiles), and imaging data (i.e. total number of lesions contained
within the infratentorial, juxtacortical, and periventricular regions
on brain MRI, the presence of gadolinium enhancing lesions
throughout the follow-up period, geographical distribution of
lesions, involvement of the spinal cord) on the time to the first
symptomatic event. The association of each covariate with time to
the first clinical symptom was quantified by hazard ratios (HR)
along with their 95% confidence intervals (CI).
A p value ,0.05 was considered significant.
Results
A total of 456 RIS subjects were identified. Table 2 summarizes
the cases by center and country of origin. Five subjects with neuro-
imaging studies dated before 1990 were excluded, resulting in 451
cases available for the primary analysis.
The study cohort was principally comprised of women (F: 354
(78.5%)) who were white (86%). The mean age when the first
abnormal MRI occurred was 37.2 years (y) (median: 37.1 y, range:
11–74 y) with mean clinical follow-up time of 4.4 y (median: 2.8 y,
range: 0.01–21.2 y). A positive family history for MS was observed
in 10.0% of the study group. A total of 31 subjects had EDSS
scores .0.0 on the initial baseline examination (Table 3) resulting
from the identification of disc pallor on funduscopic examination,
mild alterations in visual acuity, mild deficits in vibratory
sensation, mild urinary complaints or constipation, depression,
fatigue, or pyramidal function system scores .0.0 due to weakness
secondary to peripheral neurological disorders. CSF profiles were
obtained in 67% (300/451) of all RIS cases. Abnormal CSF
profiles were identified in 64.7% (194/300) of samples acquired.
The baseline characteristics of the core study cohort are
summarized in Table 3.
Reasons for the initial brain MRI were diverse (Table S1).
Imaging on the spinal cord was ordered at the discretion of the
referring or treating physician at each study site with cervical (326;
72.3%) and thoracic (171; 37.9%) MRI studies performed. Table 3
summarizes the radiological characteristics of the study cohort.
The 5-year observed first acute or progressive clinical event rate
on the whole study population was 34% (standard error (SE) = 3%)
(Figure 1). In all subjects experiencing clinical events, symptoms
appeared to be consistent with a demyelinating event. The results
of the Kaplan-Meier survival analyses did not reveal different
temporal profiles of evolution to the first symptomatic event
(p=0.40) between all centers over the course of follow-up from
RIS diagnosis. In addition, no significant differences related to the
reason that induced the MRI with RIS evidence were detected (p
for heterogeneity = 0.76).
Of the 451 cases included in the analysis, 14 individuals who,
after experiencing their first clinical symptom, experienced at least
12-months of progressive neurological decline during the entire
follow-up period and fulfilled criteria for primary progressive MS
[15] (median age = 43.8 y (interquartile range: 40.7–57.3), sex
(male) (50%), white (92.7%)). A total of 9 cases were identified
within the first 5 years from the initial MRI demonstrating the
Table 1. Inclusion and exclusion criteria for study subjects.
Inclusion criteria Exclusion criteria
RIS subjects of all ages MRI scan date ,1990
Incidental anomalies identified on MRI of the brain or spinal cord with the
primary reason for the acquired MRI resulting from an evaluation of a
condition other than MS
Incomplete medical history or radiological data
CNS white matter anomalies meeting the following criteria: History of remitting clinical symptoms consistent with multiple sclerosis lasting .
24 hours prior to CNS imaging with anomalies suggestive of MS
a. Ovoid, well-circumscribed, and homogeneous foci with or without
involvement of the corpus callosum
b. T2-hyperintensities measuring .3 mm2 and fulfilling 3 or 4 Barkhof
Criteria for dissemination in space
c. CNS anomalies not consistent with a vascular pattern
MRI anomalies do not account for clinically apparent impairments CNS MRI anomalies are better accounted for by another disease process
doi:10.1371/journal.pone.0090509.t001
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incidental anomalies, representing 9.6% of all subjects experienc-
ing a first event.
Results of the univariate and multivariate Cox regression
models are reported in Table 4. The following variables were
included in the multivariate analysis: age, sex, positive MS family
history, ethnicity, abnormal CSF, presence of periventricular
lesions, presence of infratentorial lesions, presence of juxtacortical
lesions, cervical or thoracic spinal cord lesion, and contrast
enhancement on the initial MRI revealing the incidental
anomalies highly suggestive of MS. A younger age at RIS
diagnosis was associated with an increased risk of developing an
initial symptomatic event [hazard ratio (HR): 0.98 (95% CI: 0.96–
0.99); p=0.03] with an estimated risk of developing an event
decreasing by 2% for every year additional year of age. In
addition, the presence of either a cervical or thoracic spinal cord
lesion [HR: 3.08 (95% CI: 2.06–4.62); p,0.001] constituted
significant predictors for the development of a first clinical event
(adjusted for Center and date of RIS MRI). The 5-year risk of
developing a first clinical event for RIS subjects with both spinal
cord involvement and younger age was 58% (SE= 7%). Also, men
had a higher risk compared to women [HR: 1.93 (95% CI: 1.24–
2.99); p=0.004]. Further stratification of risk within the spinal
cord revealed the independent importance of both cervical [HR:
2.02, (95% CI: 1.10–3.73, p=0.02] and thoracic spinal cord [HR:
2.23 (95% CI: 1.20–4.13), p=0.01] involvement, that were
retained together in a multivariate model. In the multivariate
model, ethnicity, a family history significant for MS, CSF profile,
lesion location (i.e. cerebellum and brainstem), and presence of
gadolinium enhancement on the baseline MRI scan were not
identified as predictors for a first clinical event. Figures 2A–C
demonstrate Kaplan-Meier survival curves for these independent
risk factors, and risk stratified by the presence of any single risk
factor, or the concomitant presence of multiple risk factors
(Figure 2D).
Table 2. Participating Centers within the Radiologically Isolated Syndrome Consortium (RISC) Research Network
and corresponding contribution of new and previously published RIS cases by region.
New Cases (n =264) Previously Reported (n=187)
United States of America (n =205)
University of California, San Francisco, San Francisco, California (n = 92) n = 21 n = 71
Mayo Clinic Medical Center, Rochester, Minnesota (n = 30) n = 21 n = 9
Mt. Sinai Medical Center, New York, New York (n = 34) n = 34 –
Barrow Neurological Institute, Phoenix, Arizona (n = 49) n = 49 –
France (n =149)
Club Francophone de la Scle´rose en Plaques
Centre Hospitalo Universitaire Pasteur, Nice, France (n = 51) n = 23 n = 28
Centre Hospitalo Universitaire Pontchaillou, Rennes, France (n = 4) n = 2 n = 2
Centre Hospitalo Universitaire Purpan, Toulouse, France (n = 9) n = 6 n = 3
Centre Hospitalo Universitaire Salengro, Lille, France (n = 25) n = 13 n = 12
Centre Hospitalo Universitaire Clermont, Clermont-Ferrand, France (n = 2) n = 1 n = 1
Centre Hospitalo Universitaire Central, Nancy, France (n = 9) n = 3 n = 6
Centre Hospitalo Universitaire Besanc¸on, Besanc¸on, France (n = 4) n = 2 n = 2
Centre Hospitalo Universitaire Strasbourg, Strasbourg, France (n = 8) n = 5 n = 3
Centre Hospitalo Universitaire tripode, Bordeaux, France (n = 10) n = 7 n = 3
Centre Hospitalo Universitaire Nantes, Nantes, France (n = 7) n = 3 n = 4
Centre Hospitalo Universitaire Timone, Marseille, France (n = 3) n = 3 –
Fondation Rothschild, Paris, France (n = 11) n = 5 n = 6
Centre Hospitalo Universitaire Reims, France (n = 3) n = 3 –
Centre Hospitalo Universitaire Montpellier Nimes, France (n = 3) n = 3 –
Italy (n =24)
University of Siena, Siena, Italy (n = 12) – n = 12
University of Florence, Florence, Italy (n = 12) – n = 12
Turkey (n=44)
University of Istanbul, Istanbul, Turkey n = 31 n = 13
Spain (n=29)
MS Center of Catalunya Cemcat, Vall d9Hebron Hospital, Barcelona, Spain n = 29 –
doi:10.1371/journal.pone.0090509.t002
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In 16.2% (73/451) of RIS subjects, approved DMTs for MS
were introduced prior to the development of a first clinical episode
with a mean treatment duration of 3.2 y (SD: 3.1 y, range: 0.1–
11 y). We identified subjects treated with interferon b-1a (30 mcg
weekly), interferon beta-1b, glatiramer acetate, fingolimod, inter-
feron beta-1a (44 mcg thrice weekly) and natalizumab, with a few
individuals exposed to more than one treatment. The 5-year risk of
developing a first clinical event for RIS subjects who were exposed
to DMTs was 45% (SE= 7%) as compared to 31% (SE= 3%) for
RIS subjects who did not receive treatment.
Discussion
The challenge within RIS involves the accurate identification of
subjects and valid predictors for a first attack. Defining risk is
associated with limitations: i). MRI scans are acquired randomly
and not during or immediately following a neurological episode,
ii). disease duration is less clear given the absence of a definable
clinical event, and iii). the temporal profile of radiological
evolution and brain plasticity in such early forms of demyelinating
disease is uncertain. Most importantly, there is a risk of the
improper classification of subjects by the over application of DIS
criteria, resulting in the incorporation of individuals with
subclinical brain anomalies originating from another disease
process [13,14,16].
Data from this retrospective study of RIS cases from the largest
existing multinational cohort, in regions of moderate to high MS
prevalence [17], suggest that a meaningful amount of subjects
evolve to a first acute or progressive clinical symptom. A younger
age at RIS identification, sex (men), and involvement of the spinal
cord, were identified as most relevant. Risk also appeared to be
higher with the presence of multiple risk factors.
In MS, age is inversely related to the time to disability levels by
shortening the latency time for attaining disability milestones
Table 3. Baseline demographic, clinical and radiological data from the entire RIS study cohort.
Cohort (n =451) Values Missing, n (%)
Mean age at RIS, y (median, range) 37.2 (37.1, [11–74] 0 (0)
Female, n (%) 354 (78.5%) 0 (0)
Ethnicity, n (%) 22 (4.9)
White 387 (85.8)
African American 6 (1.33)
Hispanic 17 (3.8)
Middle Eastern 15 (3.2)
Asian/Pacific Islander 4 (0.9)
Family History for MS, n (%) 41 (9.9) 38 (8.4)
Mean clinical follow-up time, y (median, range) 4.4 (2.8, [0.01–21.1]) 2 (0.4)
EDSS Score (%) 0 (0)
0 420 (93.1)
1 23 (5.1)
1.5 6 (1.3)
2 2 (0.4)
Abnormal CSF profile*, n (%) 194 (64.7) 151 (33.5)
Exposure to DMT, n (%) 73 (17.3) 29 (6.4)
Presence of Gd+ lesions, n (%) 108 (28.3) 70 (16)
Presence of periventricular lesions, n (%) 440 (98.7) 5 (1.1)
Presence of infratentorial lesions, n (%) 137 (30.4) 5 (1.1)
Presence of juxtacortical lesions, n (%) 400 (90.1) 7 (1.6)
Presence of spinal cord lesions lesions, n (%) 135 (35.2) 68 (15.1)
doi:10.1371/journal.pone.0090509.t003
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[18,19]. Similar outcomes are also observed in men [19].
Increasing age appeared to be important in reducing the risk for
symptom development, a plausible observation given a greater
degree of disease activity in younger patient groups, suggesting an
opportune age window for symptom development [20]. One
would anticipate an increase in lesion burden with advancing
chronological age, yet the opposite trend was appreciated
suggesting possible differences in the time of disease onset, an
imbalance between the extent of injury to the oligodendrocyte or
axon and innate compensatory mechanisms during the inflam-
matory event, or the potential influence of other mediating factors.
Asymptomatic lesions within the cervical or thoracic region
were identified to be the strongest predictor for forecasting future
clinical events [HR: 3.08 (95% CI: 2.06–4.62); p,0.001], affirming
our previous report of the importance of spinal cord involvement
[12]. The observation of lesions within the spinal cord in RIS
epitomizes the clinicoradiologic paradox. Similar discordant expe-
riences are frequently observed in MS patients when evaluating the
degree of spinal cord involvement in relation to clinical outcomes
[21]. Overall, our current and historical observations of the lack of
notable clinical events may be related to an earlier timeframe of
disease involvement (and less secondary degeneration) or related to
limitations in the imaging techniques utilized as quantitative MRI
metrics have recently been better able to classify extent of micro-
architectural injury in relation to clinical outcomes [22].
The presence of lesions within the spinal cord, together with
additional brain lesions suggestive of MS in young individuals,
increases the specificity that these anomalies are due to
demyelinating disease, being observed in a limited number of
cases in those with other neurological diseases [23]. In a recent
investigation of CIS patients without spinal cord symptoms,
imaging of the parenchyma was of clinical value diagnostically in
facilitating an earlier diagnosis and prognostically in predicting
conversion to CDMS [24]. Our results support imaging of the
cervical and thoracic spinal cord, having utility in the diagnosis of
RIS if the brain MRI study is equivocal or fails to meet DIS
criteria, and in defining risk for a future clinical event.
Contrast enhancement and infratentorial involvement on the
baseline imaging study, known to be of importance in CIS [25],
were not predictive of clinical symptom development. This
discordance may be explained by the timing of the MRI scans
with CIS patients being scanned during or immediately following
an acute neurological event or may be related a higher reserve
capacity and recovery innate to RIS subjects. Given this, a higher
proportion of MRI relapses may be required, compared to CIS, to
surpass the threshold for symptom development.
Treatment in RIS failed to demonstrate a benefit in extending the
time to the onset of the first symptomatic event. As treatment
decisions were made by referring providers and not study investiga-
tors, insights into the decision-making process and attitudes by RIS
subjects to receive such interventions, are unclear and may have been
biased. This observation is concerning given the lack of scientific data
supporting treatment along with the high costs and risks associated
with exposure. Despite the extensive existing literature supporting the
association of early MS treatment and reduction in clinical attack
rates [26–28], only a well-structured, and appropriately powered,
study would clarify this extremely relevant issue in RIS.
Interestingly, our data revealed a pre-symptomatic phase for
subjects fulfilling formal criteria for primary progressive MS [15].
Overall, there is a lack of scientific data regarding the existence
and time course of the presymptomatic phase prior to the
development of the first progressive symptom with the literature
being limited to a single case report [29]. A detailed description of
this subgroup will be provided in a separate report.
This work represents the introduction of 264 new RIS cases and
the inclusion of 8 new databases within the U.S. and Europe, in
addition to the incorporation of previously identified subjects
[3,5,7,9,10,12]. We believe there is great value in incorporating
cases from previously published reports as data were enriched in
those without clinical events by the addition of radiological and
Figure 1. Kaplan-Meier survival analysis with the endpoint of time to the first acute or progressive event at 5-years for the entire
RIS cohort.
doi:10.1371/journal.pone.0090509.g001
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Figure 2. Kaplan-Meier survival analysis with the endpoint of time to a first clinical event by (A) the presence of spinal cord lesions,
(B) age at first MRI demonstrating anomalies suggestive of demyelinating disease, (C) sex, and (D) stratified based on the presence
of 0, 1, 2, or 3 risk factors.
doi:10.1371/journal.pone.0090509.g002
Table 4. Cox regression models containing univariate and multivariate analyses of factors related to time to the
first acute or progressive clinical event.
Variable n
Univariate Analysis* HR (95%
C.I.) p
Multivariate Analysis* HR
(95% C.I.) p
Age 451 0.97 (0.96–0.99) ,0.001 0.98 (0.96–0.99) 0.009
Sex (Male) 451 1.64 (1.10–2.44) 0.015 1.93 (1.24–2.99) 0.004
Positive Family MS History 451 2.20 (1.31–3.70) 0.003
Ethnicity 451 0.99
Abnormal CSF1 300 1.78 (1.11–2.87) 0.017
Periventricular lesions presence 446 0.84 (0.21–3.90) 0.8
Infratentorial lesions presence 446 1.26 (0.88–1.83) 0.2
Juxtacortical lesions presence 444 0.94 (0.50–1.77) 0.84
Cervical or thoracic spinal cord lesion 383 3.26 (2.18–4.86) ,0.001 3.09 (2.06–4.62) ,0.001
Contrast enhancement on RIS MRI 381 1.09 (0.70–1.69) 0.70
*Adjusted for Center and date of RIS diagnosis.
HR = hazard ratio; CSF = cerebrospinal fluid.
1= IgG index .0.7 or the presence of .2 unique oligoclonal bands within the CNS.
doi:10.1371/journal.pone.0090509.t004
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clinical information acquired during routine re-evaluations. No
statistical differences in the probability of a first clinical event were
observed between new and previously reported cases. In addition,
multiple sensitivity analyses were performed to ensure that one
given center was not responsible for driving an observed effect.
The limitations of these data include the retrospective study
design and accompanying non-standardized procedures for interval
clinical surveillance, clinical evaluations following seminal clinical
events, radiological metrics, areas of the CNS being imaged, and
time intervals for repeat imaging. Our reported findings may also be
impacted by selection bias within participating centers and in
countries where MRI use is more prevalent. The differing natural
history of MS in regions where subjects were acquired, along with
clinical follow-up times of variable length for RIS subjects included
within the study cohort, may further limit the generalizability of the
observed results. In addition, formalized committees that confirmed
the presence of anomalies suggestive of MS on CNS neuroimaging
or adjudicated relapses within centers were not employed.
The need for systematically acquired data for improvements in
the classification of RIS and generation of risk algorithms are
critically important, providing the basis for scientifically supported
management, and most importantly, minimizing the amount of
improperly classified subjects exposed to unnecessary medical
testing, MS treatments, and psychological harm. Caution should
be applied in the interpretation of these data given our study
limitations and future standardized efforts are needed to verify
these findings and help to provide better estimates of risk. In time,
new approaches in the treatment of RIS may be developed, being
viewed as not only inherently sensible, but appropriate, for those at
greatest risk for a seminal clinical event.
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